[go: up one dir, main page]

HUP0202741A3 - Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation - Google Patents

Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation

Info

Publication number
HUP0202741A3
HUP0202741A3 HU0202741A HUP0202741A HUP0202741A3 HU P0202741 A3 HUP0202741 A3 HU P0202741A3 HU 0202741 A HU0202741 A HU 0202741A HU P0202741 A HUP0202741 A HU P0202741A HU P0202741 A3 HUP0202741 A3 HU P0202741A3
Authority
HU
Hungary
Prior art keywords
endometriosis
preparation
pharmaceutical composition
fallopian tube
composition available
Prior art date
Application number
HU0202741A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HUP0202741A2 publication Critical patent/HUP0202741A2/hu
Publication of HUP0202741A3 publication Critical patent/HUP0202741A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0202741A 1999-09-23 2000-09-20 Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation HUP0202741A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15547899P 1999-09-23 1999-09-23
PCT/EP2000/009212 WO2001021194A2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction

Publications (2)

Publication Number Publication Date
HUP0202741A2 HUP0202741A2 (hu) 2003-01-28
HUP0202741A3 true HUP0202741A3 (en) 2003-12-29

Family

ID=22555601

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202741A HUP0202741A3 (en) 1999-09-23 2000-09-20 Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation

Country Status (22)

Country Link
EP (1) EP1214086A2 (hu)
JP (2) JP2003509467A (hu)
KR (1) KR100772852B1 (hu)
CN (2) CN101045155A (hu)
AU (1) AU769482B2 (hu)
BG (1) BG66128B1 (hu)
BR (1) BR0014198A (hu)
CA (1) CA2383510A1 (hu)
HK (1) HK1049117A1 (hu)
HU (1) HUP0202741A3 (hu)
IL (1) IL148185A0 (hu)
MX (1) MXPA02002436A (hu)
NO (1) NO331198B1 (hu)
NZ (1) NZ534836A (hu)
PL (1) PL201898B1 (hu)
RU (1) RU2255759C2 (hu)
SK (1) SK3752002A3 (hu)
TR (1) TR200200738T2 (hu)
TW (1) TWI267373B (hu)
UA (1) UA73956C2 (hu)
WO (1) WO2001021194A2 (hu)
ZA (1) ZA200201374B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
US8318899B2 (en) 2008-01-24 2012-11-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
WO2010085145A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
CA2889475A1 (en) 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
CA2906894A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Compositions comprising elagolix for use in treating pain associated with endometriosis
KR20200109291A (ko) 2017-08-18 2020-09-22 애브비 인코포레이티드 자궁내막증, 자궁섬유증, 다낭난소증후군 또는 샘근육증을 치료하기 위한 약제학적 제형
WO2019036713A1 (en) 2017-08-18 2019-02-21 Abbvie Inc. SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS
AU2018419533A1 (en) 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
SE9301606D0 (sv) * 1993-05-07 1993-05-07 Per-Christer Oden Composition for the treatment of impaired hair growth
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
EE03515B1 (et) * 1994-07-22 2001-10-15 The Medical College Of Hampton Roads GnRH antagonist kasutamiseks gonadaalsteroid-sõltuva seisundi ravis
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
RU2108583C1 (ru) * 1996-07-29 1998-04-10 Николай Владимирович Рымашевский Способ определения показаний к проведению гормонотерапии у больных генитальным эндометриозом
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
AU729752B2 (en) * 1997-06-05 2001-02-08 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung

Also Published As

Publication number Publication date
TR200200738T2 (tr) 2002-08-21
KR100772852B1 (ko) 2007-11-02
WO2001021194A3 (en) 2002-03-14
HK1049117A1 (zh) 2003-05-02
EP1214086A2 (en) 2002-06-19
NO20021430L (no) 2002-05-07
JP2012051920A (ja) 2012-03-15
TWI267373B (en) 2006-12-01
ZA200201374B (en) 2002-10-30
HUP0202741A2 (hu) 2003-01-28
NZ534836A (en) 2007-07-27
IL148185A0 (en) 2002-09-12
MXPA02002436A (es) 2003-02-12
KR20020035879A (ko) 2002-05-15
AU769482B2 (en) 2004-01-29
JP2003509467A (ja) 2003-03-11
PL201898B1 (pl) 2009-05-29
CN101045155A (zh) 2007-10-03
PL353244A1 (en) 2003-11-03
AU7779200A (en) 2001-04-24
NO331198B1 (no) 2011-10-31
BG106584A (bg) 2003-02-28
SK3752002A3 (en) 2003-06-03
CN1376070A (zh) 2002-10-23
RU2255759C2 (ru) 2005-07-10
BR0014198A (pt) 2002-05-21
UA73956C2 (en) 2005-10-17
BG66128B1 (bg) 2011-06-30
WO2001021194A2 (en) 2001-03-29
CA2383510A1 (en) 2001-03-29
NO20021430D0 (no) 2002-03-21

Similar Documents

Publication Publication Date Title
HUP0200992A3 (en) Indoline derivatives as progesterone antagonists and pharmaceutical compositions containing them and their use
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0203142A3 (en) Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0302093A3 (en) Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy
HUP0104718A3 (en) Micronized eplerenone compositions, process for their preparation and use thereof for the preparation of pharmaceutical compositions
PL396568A1 (pl) Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny
PL355844A1 (en) Novel pharmaceutical compositions of anti-tubrcular drugs and process for their preparation
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
HUP0204226A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
CY2009015I2 (el) Φαρμακευτικος συνδυασμος αιθινυλεστραδιολης και δροπιρενονης για χρηση ως αντισυλληπτικο
HUP0101693A3 (en) Use of steroidal sapogenins and their derivatives for producing pharmaceutical compositions for the treatment of alzheimeirs disease
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
HUP0201872A3 (en) Steroid compounds and pharmaceutical compositions of the same
HUP0203311A3 (en) New pharmaceutical compositions of prolonged effect
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
HUP0202741A3 (en) Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation
IL145188A0 (en) Processes for making pharmaceutical oral ecb formulations and compositions
HUP0201116A2 (en) Erythromycin derivatives and pharmaceutical compositions containing them and their use
IL161348A (en) Substituted 4- phenyl-4-[1h - imidazol-2-yl] piperidine derivatives and their use for the preparation of pharmaceutical compositions
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0301317A3 (en) Use of neuroprotective 7-beta-hydroxysteroids for preparation of pharmaceutical compositions
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0201405A3 (en) Pharmaceutical composition for therapeutic use of melatonin
IL137275A0 (en) Pharmaceutical composition for the treatment of anal fissures
EE05317B1 (et) Etinl”stradiooli ja drospirenooni sisaldav farmatseutiline kompositsioon kasutamiseks rasestumisvastase vahendina

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ZENTARIS GMBH, DE

Free format text: FORMER OWNER(S): ZENTARIS AG., DE; ZENTARIS GMBH, DE

FD9A Lapse of provisional protection due to non-payment of fees